Xihu University Incubated Company Secures Exclusive Strategic Investment from Henan; Synthetic Biology Production Base Begins Scale-Up Construction

Recently,Henan Huirong FundAnnounce Exclusive Strategic InvestmentHangzhou Xizi Shenghe Technology Co., Ltd., successfully established a strategic partnership with the bio-manufacturing pilot base under Henan Investment Group.

Under the dual support of capital and industry, Xizi Shenghe has officially launched the planning and construction of its own large-scale production base in Henan, accelerating the transition of high-value-added bioactive ingredients from laboratory research to industrial mass production.

Synthetic biology "dark horse" incubated by Westlake University

Xizi ShengheA synthetic biology enterprise incubated and nurtured by the Future Industries Research Center of Westlake University, bringing together synthetic biologists from Jiangnan University and Zhejiang University, an AI enzyme engineering team, and senior experts in bio-manufacturing processes.

The company focuses on oral and topical anti-aging product lines. Since its establishment in 2025, month 3, we have rapidly achievedRecombinant Collagen, Rare Ginsenosides, CytidineIndependent R&D and low-cost, scalable production of high-value raw materials. From inception to full R&D and manufacturing capability, Xizi Shenghe achieved this in under a year—demonstrating remarkable technology conversion efficiency.

The synthetic biology sector is viewed as a strategic industry next in line after semiconductors. Xizi Shenghe's differentiated positioning in anti-aging ingredients has enabled it to quickly establish brand recognition among numerous synthetic biology companies.

Capital + Industry: Dual Empowerment by the Huirong Fund

In this partnership, Henan Huirong Fund's role goes beyond financial investment.

Henan Huirong Fund will leverage its post-investment industry empowerment capabilities, relying on the bio-manufacturing pilot platform of Henan Investment Group, to assist Xizi Shenghe in process scale-up and pilot validation, breaking through the "R&D – Pilot Production – Mass Productionclosed-loop industry ecosystem.

Simultaneously, Xizi Shenghe has launched the planning and construction of its own large-scale production base in Henan. Leveraging the region's fermentation industry ecosystem, energy cost advantages, and strategic location, the facility will host a scalable synthetic biology raw materials production line.

As a major province for agriculture and the food industry, Henan possesses unique advantages in the field of bio-manufacturing:Well-established raw material supply chain, controllable production costs, and ample skilled labor reserve.For synthetic biology companies, these factors directly impact cost competitiveness during the scale-up phase.

In addition, Henan Investment Group has already established a pilot-scale biomanufacturing base, providing critical support bridging the gap from laboratory research to factory production. Locating Xizi Shenghe's production facility in Henan is driven by industrial logic rather than simple investment attraction; it offers the complete ecosystem needed to transform technology into market-ready products.

Outlook: Leverage the base as a pivot to accelerate commercialization of bioactive ingredients.

After this collaboration is implemented, Xizi Shenghe will leverageHenan Pilot PlatformConduct multi-pipeline process scale-up tests while advancing the construction of our in-house production base. Once operational, the facility will continuously supply bio-synthetic ingredients such as recombinant collagen and rare ginsenosides to the skincare and functional health markets.

As synthetic biology transitions from the lab to industrial scale, pilot platforms, mass production facilities, and industry capital are all essential. The partnership between Xizi Shenghe and Henan Huirong Fund exemplifies the fusion of cutting-edge biotechnology with regional industrial strengths. We look forward to this project's successful launch, which will bring new supply to the high-value bioactive ingredients market in China and further strengthen the synthetic biology ecosystem in central China.

Biomanufacturing is reshaping the industry with unstoppable momentum.Pharmaceuticals, Medical Aesthetics, Food, Chemicals, Agriculture, Materialsmanufacturing methods across industries. From breakthroughs in synthetic biology to the deep integration of artificial intelligence and biotechnology, bio-manufacturing is recognized as a key driver of the next wave of technological and industrial transformation! We cordially invite colleagues from all sectors2027-3-10 to 12, 2027Together3rd Yitao Bio-Manufacturing Industry Conference & Exhibition (Spring)Looking forward to meeting you in person!